The combination of a large total addressable market (TAM), limited competition, and a rough start for Leqembi could all work in Lilly's favor as the company begins to scale Kisunla this year.
Altria has an impressive streak of raising its dividend for 55 consecutive years. Eli Lilly's current streak only goes back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback